Orlance

Orlance is a Seattle-based biotechnology company specializing in the development of a high-performance delivery platform for DNA and RNA vaccines and therapeutics. The company's core technology, the MACH-1 (Micro-particle Accelerated Cellular Delivery) platform, is a needle-free, next-generation gene gun that delivers nucleic acid-coated microparticles directly into the skin's immune-rich layers. This delivery method is designed to trigger robust immune responses with significantly lower doses than traditional injection methods while maintaining room-temperature stability. Orlance's current pipeline includes programs for universal influenza, COVID-19, and various oncology indications. By addressing the stability and delivery limitations of current mRNA and DNA technologies, Orlance aims to transform the accessibility and efficacy of genetic medicines.